IGC Pharma
29 hedge funds and large institutions have $6.07M invested in IGC Pharma in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 6 closing their positions.
30% more call options, than puts
Call options by funds: $359K | Put options by funds: $277K
1.74% more ownership
Funds ownership: 10.45% → 12.19% (+1.7%)
9% less funds holding
Funds holding: 32 → 29 (-3)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
23% less capital invested
Capital invested by funds: $7.9M → $6.07M (-$1.83M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$1.69M |
| 2 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$222K |
| 3 |
VF
Virtu Financial
New York
|
+$29.8K |
| 4 |
BlackRock
New York
|
+$25.4K |
| 5 |
Jane Street
New York
|
+$19.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$646K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$54.2K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$34.3K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$31K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$29K |
IGC Hedge Fund Activity: Q4 2021 in Review
29 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2021, worth a combined $6.07M — down 23% from $7.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IGC and 3 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Mirae Asset Global Investments, adding an estimated $1.69M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $646K sold.
- 29 institutional investors held IGC Pharma (IGC) as of Q4 2021, down from 32 in Q3 2021.
- Funds reported $6.07M of IGC Pharma stock for Q4 2021, down 23% quarter-over-quarter.
- 3 funds opened new IGC Pharma positions in Q4 2021 and 6 closed out, a net change of -3 holders.
- The largest IGC Pharma buyer in Q4 2021 was Mirae Asset Global Investments, an estimated $1.69M added.
- The largest IGC Pharma seller in Q4 2021 was Renaissance Technologies, an estimated $646K sold.
Based on aggregated 13F filings for Q4 2021.